Your account is not claimed yet. You can sign up with ORCID to claim your account.

Mark H Wilcox (Mark Wilcox, M H Wilcox)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 13

Top Venues

The Journal of antimicrobial chemotherapy

Open forum infectious diseases

Microbial biotechnology

Gut microbes

University of Leeds School of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Leeds School of Medicine Aug 1o 1995

United Kingdom

Professor of Medical Microbiology :: Microbiology

Publications

Hélène Marchandin, Cyril Anjou, Gaëtan Poulen, Jane Freeman, Mark H Wilcox, Hélène Jean-Pierre, Frédéric Barbut
In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile. The Journal of antimicrobial chemotherapy (2023)
William A Davis Birch, Ines B Moura, Duncan J Ewin, Mark H Wilcox, Anthony M Buckley, Peter R Culmer, Nikil Kapur
MiGut: A scalable in vitro platform for simulating the human gut microbiome-Development, validation and simulation of antibiotic-induced dysbiosis. Microbial biotechnology (2023)
Abiola Olumuyiwa Olaitan, Chetna Dureja, Madison A Youngblom, Madeline A Topf, Wan-Jou Shen, Anne J Gonzales-Luna, Aditi Deshpande, Kirk E Hevener, Jane Freeman, Mark H Wilcox, Kelli L Palmer, Kevin W Garey, Caitlin S Pepperell, Julian G Hurdle
Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile. Nature communications 14 (1) (2023)
Amanda Nadia Diniz, Loren Nery Fontoura Moura, Diogo Soares Gonçalves Cruz, Carlos Augusto Oliveira Junior, Henrique César Pereira Figueiredo, João Luís Reis Cunha, Eduardo Garcia Vilela, Edward J Kuijper, Mark H Wilcox, Francisco Carlos Faria Lobato, Rodrigo Otávio Silveira Silva
Characterization of the virulence of three novel clade 2 Clostridioides (Clostridium) difficile strains and a two-year screening in animals and humans in Brazil. PloS one 17 (8) (2022)
Maria J G T Vehreschild, Annie Ducher, Thomas Louie, Oliver A Cornely, Celine Feger, Aaron Dane, Marina Varastet, Fabien Vitry, Jean de Gunzburg, Antoine Andremont, France Mentré, Mark H Wilcox
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones. The Journal of antimicrobial chemotherapy 77 (4) (2022)
Marco-Felipe King, Amanda M Wilson, Mark H Weir, Martín López-García, Jessica Proctor, Waseem Hiwar, Amirul Khan, Louise A Fletcher, P Andrew Sleigh, Ian Clifton, Stephanie J Dancer, Mark H Wilcox, Kelly A Reynolds, Catherine J Noakes
Modeling fomite-mediated SARS-CoV-2 exposure through personal protective equipment doffing in a hospital environment. Indoor air (2021)
Mark H Wilcox, Jean Li Yan, Pedro L Gonzalez, Matthew Dryden, Gregory G Stone, Michal Kantecki
Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials. Infectious diseases and therapy (2021)
Christopher M Rooney, S Ahmed, Mark H Wilcox
Protecting the Microbiota. The Journal of infectious diseases 223 (12 Suppl 2) (2021)
Anthony M Buckley, Ines B Moura, James Altringham, Duncan Ewin, Emma Clark, Karen Bentley, Vikki Wilkinson, William Spittal, Georgina Davis, Mark H Wilcox
The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infection. The Journal of antimicrobial chemotherapy (2021)
Mark H Wilcox
Caution is warranted in using cephamycin antibiotics against recurrent Clostridioides difficile infection. Nature microbiology 5 (2) (2020)
Tanya M Monaghan, Tim J Sloan, Stephen R Stockdale, Adam Mark Blanchard, Richard David Emes, Mark H Wilcox, Rima Biswas, Rupam Nashine, Sonali Manke, Jinal Gandhi, Pratishtha Jain, Shrejal Bhotmange, Shrikant Ambalkar, Ashish Satav, Lorraine A Draper, Colin Hill, Rajpal Singh Kashyap
Metagenomics reveals impact of geography and acute diarrheal disease on the Central Indian human gut microbiome. Gut microbes 12 (1) (2020)
Matteo Bassetti, Alessandro Russo, Alessia Carnelutti, Mark H Wilcox
Emerging drugs for treating methicillin-resistant Staphylococcus aureus. Expert opinion on emerging drugs 24 (3) (2020)
Mark H Wilcox, Oliver A Cornely, Benoit Guery, Chris Longshaw, Areti Georgopali, Andreas Karas, Gbenga Kazeem, Jose Alejandro Palacios-Fabrega, Maria J G T Vehreschild
Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study. Open forum infectious diseases 6 (11) (2019)

Mark H Wilcox.css-eqlu8i{font-size:small;padding-left:4px;} (Mark Wilcox, M H Wilcox)

Publication Activity (10 Years)

Top Topics

Top Venues

Mark H Wilcox (Mark Wilcox, M H Wilcox)